Navigation Links
New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinson's Disease And Movement Disorders (MDS)
Date:6/8/2011

FRANKFURT, Germany, June 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that new data on Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the Movement Disorder Society's (MDS) 15th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada. The studies found that repeated injections of XEOMIN were safe and effective in the treatment of blepharospasm and cervical dystonia (CD) when administered at flexible dosing regimens, including more or less frequently than the standard dosing interval of 12 weeks.

Blepharospasm, also referred to as benign essential blepharospasm, and CD, also known as spasmodic torticollis, are rare conditions that possibly go undiagnosed or misdiagnosed. Botulinum toxin is the only FDA-approved medication for the treatment of these conditions.

The first poster presented at the meeting, titled "IncobotulinumtoxinA (NT-201) injections are safe and effective in adult subjects with blepharospasm across dosing intervals in a repeated dose-study," concludes that XEOMIN was safe and effective in the treatment of blepharospasm across dosing regimens, including injection intervals of up to 10 weeks, 10 to 12 weeks and more than 14 weeks (the approved reinjection frequency is 12 weeks or more). [Poster 609, June 8, 2011, 9 a.m. – 6 p.m.; Poster Presentation, 1:30 p.m. – 3 p.m.].

Additionally, the poster titled, "IncobotulinumtoxinA (NT-201) injections are safe and effective in adult subjects with cervical dystonia across dosing intervals in a repeated dose-study," concludes that XEOMIN was safe and effective in the treatment of CD when administered according to a flexible dosing regimen, including up to 10 weeks, 10 to 12 weeks and more than 14 weeks (the approved reinjection frequency is 12 weeks or more).[Poster 625, June 8, 2011, 9 a.m. – 6 p.m.; Poster Presentation, 1:30 p.m. – 3 p.m.]
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
10. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
11. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... N.J. , March 27, 2015  Johnson & Johnson ... Shareholders at 10 a.m. (Eastern Time) on Thursday, April 23, ... N.J. Investors and other interested parties ... visiting the Company,s website at www.jnj.com and clicking ... from the meeting will be made available a few hours ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
(Date:3/26/2015)... WASHINGTON , March 26, 2015 "Whether ... potentially patients one day." In a single ... and chief scientific officer at Pfizer,s Centers for ... researchers and scientists fueling progress at America,s biopharmaceutical companies. ... to work side-by-side with academia, patient foundations and the ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... Results from two prospective, double-blind placebo controlled multi-center ... pooled European efficacy and safety data in patients with ... presented at the American Academy of Neurology,s (AAN) 61st ... by Merz Pharmaceuticals, which plans to file a Biologic ...
... AS, the human antibody,therapeutics company, announced today that ... were presented by its,collaboration partner Peregrine Pharmaceuticals at ... Cancer Research (AACR) 2009 held during April,18 - ... of PGN635 and PGN632,provided further confirmatory evidence that ...
Cached Medicine Technology:Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 3Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 4Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 5Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies 2
(Date:3/28/2015)... March 28, 2015 Take a bite ... kicks into action. Acids tumble into the stomach, ready ... faulty valve-like structure lets these acids run amok, triggering ... extremely common symptom. More than 60 million Americans have ... examine where heartburn starts, and how it can be ...
(Date:3/28/2015)... 28, 2015 Emergency Medical Care (EMC), ... in Manhattan, recently commemorated its three-year anniversary of being ... In addition to 24-hour urgent care, Emergency Medical Care ... At this time, Emergency Medical Care’s Urgent Care ... chest pain, eye injuries, ear infections, fevers, insect bites, ...
(Date:3/28/2015)... March 28, 2015 Pitching speed, player’s height, ... of shoulder and elbow injuries, according to new research released ... AOSSM ) Specialty Day. , “Our findings indicate that a ... increase in likelihood of a history of injury, a 10 ... 12% increase likelihood of a history of injury, and playing ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
Breaking Medicine News(10 mins):Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
... HealthDay Reporter , MONDAY, Nov. 8 (HealthDay News) -- ... must make in order to breast-feed is their sleep. But ... The study, published online Nov. 8 in the journal ... amount of time whether they were breast-feeding or formula-feeding. ...
... The use of statins among a group of postmenopausal ... to the results of a prospective analysis of data from ... results of our study are consistent with the majority of ... among users of statins," said Michael S. Simon, M.D., professor ...
... found that chemicals used to line junk food wrappers ... being ingested by people where they are contributing to ... acids or PFCAs are the breakdown products of chemicals ... ranging from kitchen pans to clothing to food packaging. ...
... (HealthDay News) -- Among certain patients with a history ... Pradaxa (dabigatran) appears to be as effective as the ... German research reveals. Specifically, the new study suggests ... stroke as effectively as warfarin among those facing an ...
... Breast cancer patients are more likely to have joint pain ... cancer, according to a study presented at the American College ... study is one of the first to identify factors that ... from AI therapy. AIs, the standard adjuvant therapy for ...
... an amphibious fish stays alive for up to two months on ... fishonly about an inch or two longthat live in temporary pools ... Florida. During dry seasons when their pools disappear, the fish hole ... stay moist, they can survive for extended periods out of water ...
Cached Medicine News:Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 2Health News: Breast-Feeding Won't Rob Mom of Sleep: Study 3Health News:Statins did not reduce colorectal cancer in WHI analysis 2Health News:Dangerous chemicals in food wrappers likely migrating to humans: U of T study 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 2Health News:New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients 3Health News:Study sheds light on aromatase inhibitor joint pain syndrome 2Health News:Study sheds light on aromatase inhibitor joint pain syndrome 3Health News:Special skin keeps fish species alive on land 2
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: